#USA #New York #securities lawsuit #Faruqi & Faruqi #Nektar Therapeutics

Critical Update for Nektar Therapeutics Investors

Nektar Therapeutics, Inc. (NASDAQ: NKTR) finds itself under scrutiny as Faruqi & Faruqi, LLP, a prominent securities law firm, intensifies its investigation regarding potential claims against the company. The firm is calling attention to an impending deadline for investors who suffered losses in Nektar's securities to participate in a class action lawsuit, which is set for May 5, 2026.

Understanding the Legal Context

This legal action emerged in light of allegations that Nektar and its executives violated federal securities laws. Key claims include making misleading statements and failing to disclose critical information concerning the REZOLVE-AA trial of their investigational drug rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator. As per the allegations, the company did not adhere to proper standards during the trial, leading to results that were overstated and ultimately resulted in financial losses for investors.

Context of the Allegations

On December 16, 2025, Nektar issued a press release revealing that the Phase 2b REZOLVE-AA trial had not reached statistical significance, a revelation that was partly attributed to the inclusion of ineligible patients in the trial. Following this announcement, Nektar's stock price plummeted by 7.77%, shedding $4.14 per share, and closing at $49.16. This dramatic decline raised alarms among investors, prompting legal action and investigations.

Your Rights as an Investor

Faruqi & Faruqi emphasizes that investors who acquired Nektar securities between February 26, 2025, and December 15, 2025, are encouraged to speak with a representative about their legal options. The role of lead plaintiff, responsible for directing the case on behalf of other investors, is open to individuals who suffered significant losses. It’s crucial for any member of the class to be aware that opting to serve as lead plaintiff is not a requirement for participating in any potential settlements or recoveries from the ongoing litigation.

How to Get Involved

Investors wishing to get more information or join the class action are invited to reach out directly to attorney Josh Wilson at Faruqi & Faruqi. Contact numbers include 877-247-4292 or 212-983-9330 (Ext. 1310). Furthermore, Faruqi & Faruqi is also eager to hear from whistleblowers, former employees, and anyone who can provide insights into Nektar's practices during the pertinent time frame.

Conclusion

The upcoming May 5, 2026 deadline poses a crucial opportunity for investors affected by Nektar Therapeutics' alleged discrepancies to assert their rights and seek redress. As the situation unfolds, it serves as a pivotal moment for both the company and its investors in navigating the complexities of securities law and investor protection. Keeping abreast of these developments is essential for all stakeholders involved.

For ongoing updates regarding the Nektar Therapeutics situation, visit Faruqi & Faruqi's dedicated class action page or follow them on social media. Remember, informed decisions are key in times of uncertainty regarding investment and legal matters.